TITLE

ROSETTA/WEIZMAN INSTITUTE IDENTIFY ROLE OF MICRORNA

PUB. DATE
August 2007
SOURCE
Worldwide Biotech;Aug2007, Vol. 19 Issue 8, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that the role of microRNA was identified by scientists from the Weizman Institute of Science and Rosetta Genomics in North Brunswick, New Jersey. The findings suggested the potential for microRNA to be used as a drug candidate in cancer therapy to increase apoptosis in the context of the potent tumor suppressor p53. The results indicated that overexpression of miR-34a promoted other important anti-proliferative activities and led to increased cancer cell death.
ACCESSION #
25887428

 

Related Articles

  • Rosetta cites study on microRNA.  // Medical Device Daily;7/24/2007, Vol. 11 Issue 139, p8 

    The article reports on the findings of a clinical study conducted by Rosetta Genomics about the potential of microRNA to be used as a drug candidate in cancer therapy. It mentions that researchers have introduced miR-34a into human cancer cell lines to identify its impact on tumor cell behavior....

  • Agreements roundup.  // Medical Device Daily;6/30/2011, Vol. 15 Issue 121, p3 

    The article reports on the collaboration agreement entered into by Rosetta Genomics of Philadelphia and the University of California Davis for the development of microRNA profile for muscle-invasive bladder cancer.

  • microRNA-based assays focus of several poster presentations.  // Medical Device Daily;4/16/2008, Vol. 12 Issue 74, p4 

    The article discusses the highlights of 2008 annual American Association of Cancer Research conference in San Diego, California. Focus is given on the presentations made by Rosetta Genomics concerning its microRNA-based technologies and its possible application in the development of diagnostic...

  • Financings Roundup.  // BioWorld Today;1/21/2010, Vol. 21 Issue 13, p6 

    The article announces that Rosetta Genomics Ltd. has made a 5.1 million U.S. dollars worth of registered direct offering with institutional investors.

  • Financings Roundup.  // BioWorld Today;2/18/2011, Vol. 22 Issue 34, p2 

    The article reports that Rosetta Genomics Ltd. has agreements with investors for the sale of securities worth 6 million U.S. dollars.

  • Rosetta Genomics looking to shed $4M in operating costs.  // Medical Device Daily;10/8/2010, Vol. 14 Issue 196, p9 

    This article reports on the launch of a corporate restructuring by Rosetta Genomics to reduce its operating costs.

  • MicroRNA Diagnostics.  // Technology Review;Sep2008, Vol. 111 Issue 5, p36 

    The article evaluates the MicroRNA test for lung cancer from Rosetta Genomics.

  • Rosetta to raise $1.9M in private placement.  // Medical Device Daily;10/14/2011, Vol. 15 Issue 197, p2 

    The article reports on the 1.9 million U.S. dollar private placement of securities by Rosetta Genomics.

  • OTHER NEWS TO NOTE.  // BioWorld Today;5/1/2009, Vol. 20 Issue 83, p3 

    This section offers news briefs related to the pharmaceutical industry. Axentis Pharma AG has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for Fluidosomes-tobramycin. The FDA has approved the biologics license application of Medicis and Ipsen SA for Dysport....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics